GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vapotherm Inc (OTCPK:VAPO) » Definitions » Debt-to-EBITDA

Vapotherm (Vapotherm) Debt-to-EBITDA : -7.23 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Vapotherm Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vapotherm's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.41 Mil. Vapotherm's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $109.98 Mil. Vapotherm's annualized EBITDA for the quarter that ended in Dec. 2023 was $-15.56 Mil. Vapotherm's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -7.22.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Vapotherm's Debt-to-EBITDA or its related term are showing as below:

VAPO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.27   Med: -1.04   Max: -0.57
Current: -3.27

During the past 8 years, the highest Debt-to-EBITDA Ratio of Vapotherm was -0.57. The lowest was -3.27. And the median was -1.04.

VAPO's Debt-to-EBITDA is ranked worse than
100% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.245 vs VAPO: -3.27

Vapotherm Debt-to-EBITDA Historical Data

The historical data trend for Vapotherm's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vapotherm Debt-to-EBITDA Chart

Vapotherm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -1.05 -1.26 -1.04 -1.09 -3.27

Vapotherm Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.59 -2.04 -2.93 -2.97 -7.23

Competitive Comparison of Vapotherm's Debt-to-EBITDA

For the Medical Devices subindustry, Vapotherm's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vapotherm's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vapotherm's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vapotherm's Debt-to-EBITDA falls into.



Vapotherm Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vapotherm's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.414 + 109.978) / -34.357
=-3.27

Vapotherm's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.414 + 109.978) / -15.556
=-7.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Vapotherm  (OTCPK:VAPO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Vapotherm Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Vapotherm's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Vapotherm (Vapotherm) Business Description

Traded in Other Exchanges
N/A
Address
100 Domain Drive, Exeter, NH, USA, 03833
Vapotherm Inc is a medical technology company based in the United States. It is mainly engaged in the development and commercialization of its proprietary Hi-VNI technology products that are used to treat patients of all ages suffering from respiratory distress. The company offers four versions of its Precision Flow systems: Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox. It generates revenue primarily from sales of proprietary Precision Flow systems to hospitals through a direct sales organization in the United States and distributors in select countries outside of the United States.
Executives
Joseph Army director, officer: President and CEO ONE WASHINGTON CENTER, SUITE 400, DOVER NH 03820
Anthony L. Arnerich director 100 DOMAIN DRIVE, EXETER NH 03833
Dorota Mckay officer: Chief Accounting Officer 100 DOMAIN DRIVE, EXETER NH 03833
John Landry officer: See Remarks 100 DOMAIN DRIVE, EXETER NH 03833
James W Liken director 5 DEER SPRING LANE, PITTSBURGH PA 15211
Lance A Berry director 5677 AIRLINE ROAD, ARLINGTON TN 38002
Elizabeth H Weatherman director C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Richard R Barrera 10 percent owner 767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Roystone Capital Holdings Llc 10 percent owner 767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Roystone Capital Management Lp 10 percent owner 780 THIRD AVENUE, 41ST FLOOR, NEW YORK NY 10017
Brian Lawrence officer: SVP & Chief Technology Officer 100 DOMAIN DRIVE, EXETER NH 03833
Prescott General Partners Llc 10 percent owner, other: Member of Section 13(d) Group 2200 BUTTS ROAD, SUITE 320, BOCA RATON FL 33431
Gregoire Ramade officer: Vice President, International 100 DOMAIN DRIVE, EXETER NH 03833
Joel F. Dube officer: Chief Accounting Officer 100 DOMAIN DRIVE, EXETER NH 03833
Donald J Spence director C/O OAKMONT ACQUISITION CORP., 33 BLOOMFIELD HILLS PARKWAY, SUITE 240, BLOOMFIELD HILLS MI 48304